Strategy At Novartis: Culture Change As The 'How' Behind The 'What'
• By William Looney
If strategic planning is a necessary hedge against the drawn-out, asset-draining product cycles of today’s big pharma enterprise, then what is the secret of doing it well? In Vivo looks for answers in a conversation with Novartis strategy lead Stephen Moran.
Stephen Moran, Global Head of Strategy for Novartis • Source: Novartis AG
This article is part of the Outlook 2019 series – an annual collection provided exclusively to subscribers of Informa Pharma Intelligence publications.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.
From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.
Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.
Industry is trying to side-step President Trump’s tariff- and price-curbing policy proposals. It may do better facing up to enduring R&D productivity and drug affordability challenges.